Literature DB >> 10804293

Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line.

K Kusuzaki1, G Minami, H Takeshita, H Murata, S Hashiguchi, T Nozaki, T Ashihara, Y Hirasawa.   

Abstract

Overcoming multidrug resistance (MDR) is an urgent issue to improve the prognosis of osteosarcoma patients. In this study, we undertook to clarify the effect of photodynamic therapy (PDT) with acridine orange (AO) on the MDR mouse osteosarcoma (MOS / ADR1) cell line, by comparing the outcome with the effect on a chemosensitive osteosarcoma (MOS) cell line. Cultured cells of MOS and MOS / ADR1 cell lines were exposed to AO at various concentrations for various times, followed by long- or short-term (10 or 1 min) illumination with blue light (466.5 nm) for excitation. Living cells were counted by means of the trypan blue exclusion test. The results showed that AO rapidly bound to DNA, RNA and lysosomes of living MOS and MOS / ADR1 cells and also that most tumor cells in both cell lines died rapidly (viability ratio to untreated cells: 1/1000) within 48 h under conditions of continuous or 15-min flash exposure to AO at concentrations above 1.0 microg/ml plus 10-min illumination with blue light. Even after flash exposure to AO at concentrations above 1.0 microg/ml plus 1-min illumination, the viability of MOS/ADR1 cells decreased to a viability ratio of less than 1/ 1000 within 72 h. Based on these results, we concluded that AO with photo-excitation has a strong cytocidal effect, not only on chemosensitive mouse osteosarcoma cells, but also on MDR mouse osteosarcoma cells. These results suggested that photodynamic therapy with AO may be a new approach to treating MDR human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804293      PMCID: PMC5926471          DOI: 10.1111/j.1349-7006.2000.tb00964.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

1.  Structural considerations in the interaction of DNA and acridines.

Authors:  L S LERMAN
Journal:  J Mol Biol       Date:  1961-02       Impact factor: 5.469

2.  In vivo staining and retardation of tumors in mice by acridine compounds.

Authors:  M R LEWIS; P P GOLAND
Journal:  Am J Med Sci       Date:  1948-03       Impact factor: 2.378

3.  Photodestruction of mouse epithelial tumors after oral acridine orange and argon laser.

Authors:  S H Tomson; E A Emmett; S H Fox
Journal:  Cancer Res       Date:  1974-11       Impact factor: 12.701

4.  Fluorescence microscopy of lysosomes and related structures in living cells.

Authors:  A V Zelenin
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

5.  Prognostic significance of DNA ploidy pattern in osteosarcomas in association with chemotherapy.

Authors:  K Kusuzaki; H Takeshita; H Murata; M Hirata; S Hashiguchi; T Ashihara; Y Hirasawa
Journal:  Cancer Lett       Date:  1999-03-22       Impact factor: 8.679

6.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.

Authors:  G Bacci; P Picci; P Ruggieri; M Mercuri; M Avella; R Capanna; A Brach Del Prever; A Mancini; F Gherlinzoni; G Padovani
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

7.  Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy.

Authors:  G Bacci; P Picci; S Ferrari; M Orlandi; P Ruggieri; R Casadei; A Ferraro; R Biagini; A Battistini
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

8.  Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters.

Authors:  L E Buckingham; M Balasubramanian; A R Safa; H Shah; P Komarov; R M Emanuele; J S Coon
Journal:  Int J Cancer       Date:  1996-01-03       Impact factor: 7.396

9.  Photodynamic DNA strand breaking activities of acridine compounds.

Authors:  Y Iwamoto; T Itoyama; K Yasuda; T Morita; T Shimizu; T Masuzawa; Y Yanagihara
Journal:  Biol Pharm Bull       Date:  1993-12       Impact factor: 2.233

10.  Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.

Authors:  H Takeshita; M C Gebhardt; D S Springfield; K Kusuzaki; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1996-03       Impact factor: 5.284

View more
  12 in total

Review 1.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  In vivo anti-tumor activity of photodynamic therapy with intravenous administration of acridine orange, followed by illumination with high-power flash wave light in a mouse osteosarcoma model.

Authors:  Haruhiko Satonaka; Katsuyuki Kusuzaki; Takao Matsubara; Ken Shintani; Tomoki Nakamura; Akihiko Matsumine; Takahiro Iino; Atsumasa Uchida
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

3.  Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection?

Authors:  Takao Matsubara; Katsuyuki Kusuzaki; Akihiko Matsumine; Tomoki Nakamura; Akihiro Sudo
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

4.  Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth.

Authors:  Ken Takeda; Toshiyuki Kunisada; Shinichi Miyazawa; Yoshinori Nakae; Toshifumi Ozaki
Journal:  Clin Orthop Relat Res       Date:  2008-05-09       Impact factor: 4.176

5.  Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.

Authors:  J Duanmu; J Cheng; J Xu; C J Booth; Z Hu
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

Review 6.  A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.

Authors:  Wei Yu; Jian Zhu; Yitian Wang; Junjie Wang; Weijing Fang; Kaishun Xia; Jianlin Shao; Minzu Wu; Bing Liu; Chengzhen Liang; Chengyi Ye; Huimin Tao
Journal:  Oncotarget       Date:  2017-06-13

7.  Treatment of canine osseous tumors with photodynamic therapy: a pilot study.

Authors:  S Burch; C London; B Seguin; C Rodriguez; B C Wilson; S K Bisland
Journal:  Clin Orthop Relat Res       Date:  2009-01-22       Impact factor: 4.176

8.  Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a.

Authors:  Patrick Ming-Kuen Tang; Dong-Mei Zhang; Ngoc-Ha Bui Xuan; Stephen Kwok-Wing Tsui; Mary Miu-Yee Waye; Siu-Kai Kong; Wing-Ping Fong; Kwok-Pui Fung
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

9.  Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (Review).

Authors:  Xianghong Zhang; Tang Liu; Zhihong Li; Xiangsheng Zhang
Journal:  Oncol Lett       Date:  2014-07-09       Impact factor: 2.967

10.  Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model.

Authors:  Stefania Lenna; Chiara Bellotti; Serena Duchi; Elisa Martella; Marta Columbaro; Barbara Dozza; Marco Ballestri; Andrea Guerrini; Giovanna Sotgiu; Tommaso Frisoni; Luca Cevolani; Greta Varchi; Mauro Ferrari; Davide Maria Donati; Enrico Lucarelli
Journal:  J Exp Clin Cancer Res       Date:  2020-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.